The DOI matches its Crossref record; 237 of the 237 references it cites were found in a registry or an index; 90 of the 249 sources its claims cite were checked for support.
The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer
Open accessAbstract
Advances in antibody-drug conjugate (ADC) technology and identification of new antigen targets are repositioning ADCs as a promising therapeutic platform for metastatic castration-resistant prostate cancer (mCRPC). This review summarizes recent progress in ADC payload and linker chemistry, highlights membrane antigens in prostate cancer that have demonstrated encouraging antitumor activity in clinical trials, and addresses strategies to mitigate off-target toxicity. These advances position ADCs to transform the therapeutic landscape of mCRPC.
Overview
CoChat Summary
## TL;DR
This is a narrative review of antibody-drug conjugates (ADCs) for prostate cancer, focused on payloads, linker chemistry, and molecular targets most relevant to metastatic castration-resistant prostate cancer (mCRPC). It concludes that ADCs remain promising but none are yet approved for prostate cancer because safety, target heterogeneity, and payload delivery remain major barriers.
## Key findings
- The review states that ADC development in prostate cancer is being driven by advances in payload and linker chemistry and by targets such as PSMA, B7H3, STEAP1, TROP2, and CD46.
- Several early trials showed signal of activity:
- FOR46 in mCRPC: 14/31 (45%) evaluable patients had PSA50 responses, and 8/18 (44%) had tumor regression.
- ARX517 in 24 mCRPC patients: ≥50% PSA and ctDNA decline were observed at 2.8 mg/kg, with RECIST responses in 2/7 patients with measurable soft tissue disease.
- Ifinatamab deruxtecan (B7H3-DXd): among 59 evaluable heavily pretreated mCRPC patients, 15 had partial or complete responses, with average DOR 6.4 months and PFS 4.8 months.
- Some ADC programs were stopped because of toxicity or limited benefit:
- MLN2704 had 71% dose-limiting peripheral neuropathy and was discontinued.
- PSMA ADC had 24% grade ≥3 neurotoxicity, 8% neutropenia, and 3 sepsis-related deaths.
- ASG-5ME caused substantial toxicity, including 2 treatment-related deaths, and was discontinued.
- The review highlights that 177Lu-PSMA-617 improved median overall survival and radiographic PFS versus best standard of care in VISION and is FDA-approved, underscoring the importance of PSMA as a validated prostate cancer target.
## Methods
- Narrative review of ADCs for prostate cancer, synthesizing preclinical and clinical evidence on payloads, linker technologies, and molecular targets.
- Uses published clinical trial results and identifies completed and ongoing studies in prostate cancer, especially mCRPC.
- Main analysis is qualitative comparison of target biology, ADC design features, efficacy signals, and toxicity patterns across agents.
## Limitations
- The paper explicitly notes that no ADCs have yet been approved for prostate cancer because of safety and specificity issues.
- It states that mCRPC presents intrinsic challenges for ADCs: dense stroma, low vascularity, and high intertumor heterogeneity limit penetration and distribution.
- Evident from the text: much of the prostate cancer evidence is early-phase, often with small cohorts, and several agents have no prostate-cancer-specific published data yet, limiting definitive conclusions.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
69 Valid · 8 Not valid · 103 Not checked · 9 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Auristatins, such as monomethyl auristatin E (MMAE), monomethyl auristatin F (MMAF), and Duostatin-5, inhibit tubulin polymerization;”
§ The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer > ADC cytotoxic payloads > Microtubule-disrupting agents: Auristatin, Maytansinoid, and Tubulysin
What the sources say
- Disputedcites [10] Wang, Z., Li, H., Gou, L., Li, W. & Wang, Y. Antibody-drug conjugates: Recent advances in payloads. Acta Pharm. Sin. B 13, 4025–4059 (2023). sourceExperimental — accuracy not yet measured
In “Microtubules targeting payloads” (page unavailable), the paper calls MMAE and MMAF “tubulin polymerization enhancers,” explicitly contrasting them with polymerization inhibitors. That contradicts the claimed mechanism for MMAE and MMAF. The passages do not mention Duostatin-5, so its mechanism cannot be assessed from this copy. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Not checked — no full text of the sourcecites [19] Pettit, G. R. et al. Antineoplastic agents 365. Dolastatin 10 SAR probes. Anticancer Drug Des. 13, 243–277 (1998).
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Disruption of microtubule-facilitated movement and segregation of chromosomes during mitosis induces mitotic arrest and apoptosis in rapidly dividing cancer cells10,12.”
§ The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer > ADC cytotoxic payloads > Microtubule-disrupting agents: Auristatin, Maytansinoid, and Tubulysin
What the sources say
- Supportedcites [10] Wang, Z., Li, H., Gou, L., Li, W. & Wang, Y. Antibody-drug conjugates: Recent advances in payloads. Acta Pharm. Sin. B 13, 4025–4059 (2023). source
The “Microtubules targeting payloads” section (page unavailable) says tubulin inhibitors disrupt microtubules and the mitotic spindle, arrest cells in G2/M, and ultimately lead to apoptosis. It also says these inhibitors are more toxic to rapidly dividing cancer cells than to slow-growing normal cells. The claim’s chromosome-movement wording paraphrases the spindle’s role in mitosis. (LLM, conf=0.90)
- Not checked yetcites [12] Janke, C. & Magiera, M. M. The tubulin code and its role in controlling microtubule properties and functions. Nat. Rev. Mol. Cell Biol. 21, 307–326 (2020). source
Checked before — its earlier verdict is held back until a new check runs.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Advanced tumors often become castration-resistant and refractory to conventional androgen-deprivation therapy (ADT)4.”
§ The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer > Introduction
What the sources say
- Partly supportedcites [4] Fujita, K. & Nonomura, N. Role of androgen receptor in prostate cancer: A review. World J. Mens. Health 37, 288–295 (2019). sourceExperimental — accuracy not yet measured
The “Changes of Androgen Receptor in Prostate Cancer” section says some high-risk prostate cancers progress to castration-resistant disease and grow despite castrate androgen levels. This supports resistance to conventional androgen-deprivation therapy, but the passage does not establish that advanced tumors *often* do so. (LLM, conf=0.82)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Taxanes have also been reported in preclinical models of prostate cancer to inhibit nuclear translocation of the androgen receptor (AR), thereby decreasing the pro-tumorigenic transcriptional activity of AR14,15.”
§ The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer > ADC cytotoxic payloads > Microtubule-disrupting agents: Auristatin, Maytansinoid, and Tubulysin
What the sources say
- Supportedcites [14] Zhu, M. L. et al. Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res 70, 7992–8002 (2010). source
In the Results section on AR nuclear translocation, paclitaxel blocked androgen-induced AR nuclear translocation in prostate cancer cells. The Results section on transcriptional activity reports that paclitaxel significantly inhibited androgen-response-element activation, and the Discussion links microtubule-targeting chemotherapy to impaired AR localization and activity. (LLM, conf=0.93)
- Supportedcites [15] Bai, S., Zhang, B. & Dong, Y. Impact of taxanes on androgen receptor signaling. Asian J. Androl. 21, 249–252 (2019). source
The ‘Effects of Docetaxel and Paclitaxel on AR Signaling’ section reports that paclitaxel nearly abolished androgen-induced AR nuclear translocation and reduced AR transcriptional activity in prostate cancer cells. The claim appropriately says this effect has been reported in preclinical models; the review also notes that the effect is not established for every taxane or dose. (LLM, conf=0.90)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, nearly all tumors eventually develop resistance to taxanes, mediated by mutations in tubulin, decreased microtubule bundling, and development of drug efflux pumps (e.g. P-glycoprotein)16,17.”
§ The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer > ADC cytotoxic payloads > Microtubule-disrupting agents: Auristatin, Maytansinoid, and Tubulysin
What the sources say
- Partly supportedcites [16] Maloney, S. M., Hoover, C. A., Morejon-Lasso, L. V. & Prosperi, J. R. Mechanisms of taxane resistance. Cancers (Basel) 12, 3323 (2020). sourceExperimental — accuracy not yet measured
The Concluding Remarks say that many patients do not respond initially or lose response over time—not that nearly all tumors eventually become resistant. Section 1.2.2 identifies P-glycoprotein drug efflux as a major resistance mechanism, and section 4.2 reports decreased microtubule bundling in resistant tumors. But section 4.2 says a tubulin mutation could reduce taxane binding while noting no clinical correlation with resistance; it does not establish tubulin mutations as a demonstrated mechanism in tumors. (LLM, conf=0.90)
- Not checked — no full text of the sourcecites [17] Hashemi, M. et al. Paclitaxel and docetaxel resistance in prostate cancer: Molecular mechanisms and possible therapeutic strategies. Biomed. Pharmacother. 160, 114392 (2023). source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
69 more claims · 23 with their cited sources checked
Create a free account to see all 189 claims and to verify the 40 references still open.
- It may state two separate claims as one. 111
- Probably not a substantial claim. 7
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Self-check results appear here once an independent check has confirmed them.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
“Hashemi, M. et al. Paclitaxel and docetaxel resistance in prostate cancer: Molecular mechanisms and possible therapeutic strategies. Biomed. Pharmacother. 160, 114392 (2023).”
Cited work 10.1016/j.biopha.2023.114392 · retracted 2023-04-01 · notice 10.1016/j.biopha.2023.114392 · this paper published 2025-11-14
Citations
Cites
1 retracted
Hashemi, M., Zandieh, M. A., Talebi, Y., Rahmanian, P., Shafiee, S. S., Nejad, M. M., Babaei, R., Sadi, F. H., Rajabi, R., Abkenar, Z. O., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114392 · Cited by 117
RetractedMultidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
von Minckwitz, G., Huang, C.-S., Mano, M. S., Loibl, S., Mamounas, E. P., Untch, M., Wolmark, N., Rastogi, P., Schneeweiss, A., Redondo, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1814017 · Cited by 2,625
Topoisomerase I inhibitors: camptothecins and beyond
Pommier, Y. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1977 · Cited by 2,277
Strategies and challenges for the next generation of antibody–drug conjugates
Beck, A., Goetsch, L., Dumontet, C., & Corvaïa, N. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.268 · Cited by 2,271
Tumor microenvironment as a therapeutic target in cancer
Xiao, Y., & Yu, D. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107753 · Cited by 1,957
Antibody drug conjugate: the “biological missile” for targeted cancer therapy
Fu, Z., Li, S., Han, S., Shi, C., & Zhang, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00947-7 · Cited by 1,643
(1997) · PubMed · Cited by 1,541
Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer
Watson, P. A., Arora, V. K., & Sawyers, C. L. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4016 · Cited by 1,536
Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma
Powles, T., Rosenberg, J. E., Sonpavde, G. P., Loriot, Y., Durán, I., Lee, J.-L., Matsubara, N., Vulsteke, C., Castellano, D., Wu, C., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035807 · Cited by 1,229
Research works printed but not linked: 1
- Klaassen, Z. ASCO 2025: DB‑1311/BNT324 (A Novel B7H3 ADC) in Patients with Heavily Pretreated CRPC, https://www.urotoday.com/conference-highlights/asco-2025/asco-2025-prostate-cancer/160832-asco-2025-db-1311-bnt324-a-novel-b7h3-adc-in-patients-with-heavily-pretreated-crpc.html (2025).
Cited by
Basem, Y., Ata, A., Sherif, A., Abdel-Ghany, S. E., Arneth, B. M., & Sabit, H. (2026) · Pharmaceuticals · doi:10.3390/ph19040541 · Cited by 6
“…biophysical modeling) will be essential to integrate features, stratify patients into microenvironmental phenotypes (e.g., “vascular-normalized & immune-hot”, “ECM-dense & immune-cold”, “hypoxic & myeloid-rich”), and guide therapeutic decisions (monotherapy vs. combination, sequence, dose) [162].”
Antibody–Drug Conjugates in Oncology: Principles, Clinical Development, and Future Directions
Cheng, B., Gong, L., Wang, Z. P., Peng, P., Xu, K., Huang, H., & Wu, P. (2026) · MedComm · doi:10.1002/mco2.70699 · Cited by 9
Repurposing payloads: next generation of antibody–drug conjugates
Shatzer, K., & Müller, F. L. (2026) · Trends in cancer · doi:10.1016/j.trecan.2026.04.001 · Cited by 8
Xie, D., Yang, C. C.-K., Gao, S., Li, J., Yang, J., Li, X., Jiang, R., Cao, F., Zhang, S., Wang, L., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27073287 · Cited by 6
Path dependency and the rescuing of the biomedical research enterprise
Nahle, Z. A. (2026) · Frontiers in Medical Technology · doi:10.3389/fmedt.2025.1683835 · Cited by 3
Metadata
- Authors
- Lin, C., Hadfield, M. J., Santopietro, A., Lagos, G., Cheng, L., El-Deiry, W. S., Aggarwal, R., Mega, A., Hyams, E., & Carneiro, B. A.
- Affiliations
- Brown University (US)
- University of California, San Francisco (US)
- Corresponding author
- Carneiro, Benedito A.
- ORCID
- Venue
- npj Precision Oncology
- Published
- 2025-11-14
- Volume
- 9
- Issue
- 1
- Pages
- 351-351
- ISSN
- 2397-768X (ISSN-L)
- PMC
- PMC12618892
- OpenAlex
- W4416225775
- Cited by
- 20
- References
- 228
- Citations by year
- 2026: 20
- FWCI
- 3.46
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- creativecommons.org/licenses/by-nc-nd/4.0 (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0 (vor)
- Locations
- npj Precision Oncology (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Pfizer
- AstraZeneca
- Daiichi Sankyo Europe
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- antibody-drug conjugates, prostate cancer, metastatic castration-resistant prostate cancer, linker chemistry, membrane antigens, off-target toxicity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer. https://app.cochat.ai/papers/10.1038/s41698-025-01131-0
- The paper
- Lin, C., Hadfield, M. J., Santopietro, A., Lagos, G., Cheng, L., El-Deiry, W. S., Aggarwal, R., Mega, A., Hyams, E., & Carneiro, B. A. (2025). The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer. npj Precision Oncology. https://doi.org/10.1038/s41698-025-01131-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.